Solubilization of two structurally related anticancer drugs: XK-469 and PPA

被引:16
作者
He, Y [1 ]
Tabibi, E
Yalkowsky, SH
机构
[1] Univ Arizona, Coll Pharm, Tucson, AZ 85721 USA
[2] NCI, Bethesda, MD 20892 USA
关键词
solubility; XK-469; PPA; formulation vehicle; combination; pH adjustment; cosolvency; surfactant; complexation; excipients;
D O I
10.1002/jps.20500
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The efficiency of a solubilization technique is determined by the physical-chemical properties of the drug. This study investigates the solubilization on two structurally related anticancer drugs, XK-469 and PPA. XK-469 is much less polar than PPA with an intrinsic solubility of 0.000274 mg/mL, which is about 10000 fold less than that of PPA. Fortunately, its physical-chemical properties make it much more formulatable. An ionizable drug can be solubilized. by pH adjustment with cosolvency, micellization, or complexation. Both XK-469 and PPA are weak acids with pKa values of 2.7 and 2.9, respectively. Thus, they can be solubilized by pH adjustment. At pH 4.55, neither cosolvency, micellization nor complexation has much effect on the solubility of PPA. However, these techniques can significantly increase the solubility of XK-469. In fact, the solubility of XK-469 in 20% HP beta CD at pH 4.55 is 5.85 mg/mL, which is more than 20000 times greater than its intrinsic solubility. With the solubilization descriptors obtained from the experimental data for both unionized and ionized drug species atpH 1.0 and pH 4.55, the solubility of each drug at any pH and excipient concentration can be estimated. Then, a solubilization technique can be chosen for preparing a desired final drug concentration. (c) 2005Wiley-Liss, Inc.
引用
收藏
页码:97 / 107
页数:11
相关论文
共 25 条
  • [1] Relationship between Polysorbate 80 solubilization descriptors and octanol-water partition coefficients of drugs
    Alvarez-Núñez, FA
    Yalkowsky, SH
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2000, 200 (02) : 217 - 222
  • [2] INTERACTION OF SUBSTITUTED BENZOIC-ACIDS WITH POLYSORBATE 20 MICELLES
    COLLETT, JH
    KOO, L
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 1975, 64 (07) : 1253 - 1255
  • [3] Preclinical antitumor efficacy of analogs of XK469: sodium-(2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]propionate
    Corbett, TH
    LoRusso, P
    Demchick, L
    Simpson, C
    Pugh, S
    White, K
    Kushner, J
    Polin, L
    Meyer, J
    Czarnecki, J
    Heilbrun, L
    Horwitz, JP
    Gross, JL
    Behrens, CH
    Harrison, BA
    McRipley, RJ
    Trainor, G
    [J]. INVESTIGATIONAL NEW DRUGS, 1998, 16 (02) : 129 - 139
  • [4] Induction of apoptosis by the new anticancer drug XK469 in human ovarian cancer cell lines
    Ding, ZH
    Zhou, JY
    Wei, WZ
    Baker, VV
    Wu, GS
    [J]. ONCOGENE, 2002, 21 (29) : 4530 - 4538
  • [5] High-throughput drug discovery: what can we exulect from HTS?
    Gribbon, P
    Sewing, A
    [J]. DRUG DISCOVERY TODAY, 2005, 10 (01) : 17 - 22
  • [6] Higuchi T., 1965, Interscience, New York, V4, P117
  • [7] Jinno J, 2000, J PHARM SCI-US, V89, P268, DOI 10.1002/(SICI)1520-6017(200002)89:2<268::AID-JPS14>3.3.CO
  • [8] 2-6
  • [9] SOLUBILIZATION OF A TRIPEPTIDE HIV PROTEASE INHIBITOR USING A COMBINATION OF IONIZATION AND COMPLEXATION WITH CHEMICALLY-MODIFIED CYCLODEXTRINS
    JOHNSON, MD
    HOESTEREY, BL
    ANDERSON, BD
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 1994, 83 (08) : 1142 - 1146
  • [10] Solubilization of flavopiridol by pH control combined with cosolvents, surfactants, or complexants
    Li, P
    Tabibi, SE
    Yalkowsky, SH
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 1999, 88 (09) : 945 - 947